Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05254912 · ClinicalTrials.gov registry record · Phase 2
Photoallergic Potential of 6% Bemotrizinol
A Phase 2 study, sponsored by dsm-firmenich Switzerland.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT05254912: Completed Phase 2 study, sponsored by dsm-firmenich Switzerland.
NCT05254912 is a Phase 2 study that has completed, run by dsm-firmenich Switzerland. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05254912, a Phase 2 study, has completed, sponsored by dsm-firmenich Switzerland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This clinical trial will assess the photoallergic potential of BEMT (6%), compared to a vehicle control and a negative control.
Primary Outcome
Photoallergenicity conclusions (i.e., "Photoallergic Response" or "Not a contact sensitizer or photoallergen") will based on a comparison of the reactions obtained on treated/irradiated, treated/non-irradiated and non- treated control sites. Investigational product safety will be determined through interpretation of the dermal evaluation scores. The following dermal scoring system will be used to evaluate the irradiated area within the treated test site: Grading scale for Erythema: "0" = No v
Interventions
- OTHER Vehicle
- DRUG 6% Bemotrizinol in sunscreen formulation
- DRUG 6% Bemotrizinol in petrolatum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2022-04-22 |
| Phase | Phase 2 |
What the finished NCT05254912 record still lists
NCT05254912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT05254912 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05254912 about?
NCT05254912 is a clinical study titled "Photoallergic Potential of 6% Bemotrizinol". This clinical trial will assess the photoallergic potential of BEMT (6%), compared to a vehicle control and a negative control.
What is the current status of trial NCT05254912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-03-07. Estimated completion is 2022-04-22.
What interventions are being tested in trial NCT05254912?
The interventions under investigation include: Vehicle (OTHER), 6% Bemotrizinol in sunscreen formulation (DRUG), 6% Bemotrizinol in petrolatum (DRUG).
Who is sponsoring clinical trial NCT05254912?
This trial is sponsored by dsm-firmenich Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05254912's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI